Quest picks up Texas labs, sets up national precision diagnostics center

Quest Diagnostics sign
In addition to setting up a national precision medicine center, Quest Diagnostics is working with McKesson Specialty Health on scaling a precision medicine model developed at Med Fusion. (Ed Uthman CC BY-SA 2.0)

Quest Diagnostics has completed its acquisition of a pair of laboratory businesses in Texas, establishing a foothold in the southwestern U.S. with a new national “center of excellence” for cancer precision diagnostics.

The New Jersey-based diagnostics maker announced its deals to acquire Lewisville, Texas-based Med Fusion and Clear Point in June. The pair offered diagnostic services to a range of organizations that co-owned one or both businesses, including Baylor Scott & White Health, the US Oncology Network and Texas Oncology.

"Precision medicine is changing the way we treat cancer and giving new hope to people living with the disease, but too often advanced diagnostics that facilitate the best possible care are out of reach of community oncologists and their patients," said Quest CEO Steve Rusckowski, at the time. "By partnering with McKesson Specialty Health and The Network, we will make Quest's state-of-the-art genomic analysis readily available to community oncologists everywhere.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Verily tapped by NIH to launch Obama's Precision Medicine Initiative

“This transaction will not only accelerate Quest's growth in cancer diagnostics, but also holds the promise of improving care for patients with cancer in Texas and the entire United States,” Rusckowski said.

Now, Quest is a preferred provider to these organizations—it will serve 12 BSWH hospitals in North Texas and 1,400 community-based physicians affiliated with the US Oncology Network, according to a statement.

RELATED: NIH launches database to aggregate and share genomic data for Cancer Moonshot

Quest will also collaborate with McKesson Specialty Health, which supports the Network, on standardizing gene-sequencing panels for the selection and monitoring of treatments for cancer. The duo will build on a model created by Med Fusion, which will guide a physician to a panel that is individualized to the type and stage of a patient’s cancer.

Since President Barack Obama announced the Precision Medicine Initiative in 2015, several players have been working to scale precision medicine. The NIH’s All of Us program, which seeks the health data of more than one million people, is a major part of the initiative. Meanwhile, San Francisco-based Dignity Health and Colorado-based Catholic Health Initiatives have launched the nation’s largest community-based precision medicine program—it aims to serve about 12 million patients across 150 hospitals and care systems.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.